Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

251 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Interleukin-1 antagonism moderates the inflammatory state associated with Type 1 diabetes during clinical trials conducted at disease onset.
Cabrera SM, Wang X, Chen YG, Jia S, Kaldunski ML, Greenbaum CJ; Type 1 Diabetes TrialNet Canakinumab Study Group; Mandrup-Poulsen T; AIDA Study Group; Hessner MJ. Cabrera SM, et al. Among authors: greenbaum cj. Eur J Immunol. 2016 Apr;46(4):1030-46. doi: 10.1002/eji.201546005. Epub 2016 Jan 21. Eur J Immunol. 2016. PMID: 26692253 Free PMC article. Clinical Trial.
Mixed-meal tolerance test versus glucagon stimulation test for the assessment of beta-cell function in therapeutic trials in type 1 diabetes.
Greenbaum CJ, Mandrup-Poulsen T, McGee PF, Battelino T, Haastert B, Ludvigsson J, Pozzilli P, Lachin JM, Kolb H; Type 1 Diabetes Trial Net Research Group; European C-Peptide Trial Study Group. Greenbaum CJ, et al. Diabetes Care. 2008 Oct;31(10):1966-71. doi: 10.2337/dc07-2451. Epub 2008 Jul 15. Diabetes Care. 2008. PMID: 18628574 Free PMC article.
IL-2 therapy in type 1 diabetes: "Trials" and tribulations.
Long SA, Buckner JH, Greenbaum CJ. Long SA, et al. Among authors: greenbaum cj. Clin Immunol. 2013 Dec;149(3):324-31. doi: 10.1016/j.clim.2013.02.005. Epub 2013 Feb 22. Clin Immunol. 2013. PMID: 23499139 Review.
Interleukin-1 antagonism in type 1 diabetes of recent onset: two multicentre, randomised, double-blind, placebo-controlled trials.
Moran A, Bundy B, Becker DJ, DiMeglio LA, Gitelman SE, Goland R, Greenbaum CJ, Herold KC, Marks JB, Raskin P, Sanda S, Schatz D, Wherrett DK, Wilson DM, Krischer JP, Skyler JS; Type 1 Diabetes TrialNet Canakinumab Study Group; Pickersgill L, de Koning E, Ziegler AG, Böehm B, Badenhoop K, Schloot N, Bak JF, Pozzilli P, Mauricio D, Donath MY, Castaño L, Wägner A, Lervang HH, Perrild H, Mandrup-Poulsen T; AIDA Study Group. Moran A, et al. Among authors: greenbaum cj. Lancet. 2013 Jun 1;381(9881):1905-15. doi: 10.1016/S0140-6736(13)60023-9. Epub 2013 Apr 5. Lancet. 2013. PMID: 23562090 Free PMC article. Clinical Trial.
Molecular signatures differentiate immune states in type 1 diabetic families.
Chen YG, Cabrera SM, Jia S, Kaldunski ML, Kramer J, Cheong S, Geoffrey R, Roethle MF, Woodliff JE, Greenbaum CJ, Wang X, Hessner MJ. Chen YG, et al. Among authors: greenbaum cj. Diabetes. 2014 Nov;63(11):3960-73. doi: 10.2337/db14-0214. Epub 2014 Apr 23. Diabetes. 2014. PMID: 24760139 Free PMC article.
251 results